None of the neuromyelitis optica spectrum disorder (NMOSD) patients in the Phase 3 CHAMPION-NMOSD clinical trial have had a disease relapse while on Ultomiris (ravulizumab-cwvz) treatment for a median of more than 2.5 years. These findings were shared by Sean Pittock, MD, the trial’s principal investigator, at the…
News
International research has uncovered a series of immune-related events that might contribute to the abnormal immune responses against the aquaporin-4 protein (AQP4), which drives neuroinflammation in cases of neuromyelitis optica spectrum disorder (NMOSD). Among the implicated immune cell types are natural killer T-cells (NKT), which seem to be first…
Three months of ginseng tablets taken twice a day lessened fatigue in people with neuromyelitis optica spectrum disorder (NMOSD), a placebo-controlled Phase 3 clinical trial found. Ginseng is a plant that has been used in traditional Chinese medicine for thousands of years. “This study revealed positive effects of ginseng…
A severe attack or a higher annual relapse rate before starting azathioprine or mycophenolate mofetil (MMF) was associated with a poor response in people with neuromyelitis optica spectrum disorder (NMOSD), a small study shows. An unsatisfactory response to either treatment, defined as a severe relapse or two or more…
The U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvz) to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against the aquaporin-4 (AQP4) protein. About 75% of people with NMOSD produce antibodies that bind to AQP4, according to the therapy’s developer, Alexion…
A significant proportion of neuromyelitis optica spectrum disorder (NMOSD) patients in the U.S. lost employment, work hours, and wages after their diagnosis, as motor and visual disability and symptoms like pain and fatigue hurt their productivity, a study has found. Older patients, those using mobility aids, and those…
People with neuromyelitis optica spectrum disorder (NMOSD) who have experienced only one relapse tend to underestimate their risk of future relapses, but patients who’ve had multiple relapses tend to overestimate this risk, a small study has found. The findings underscore the importance of clear communication with healthcare providers so…
Under normal circumstances, immune B-cells train T-cells, another type of immune cell, on which targets not to attack, preventing the development of neuromyelitis optica spectrum disorder (NMOSD), according to a study in mice. This training occurs in the thymus gland, a small organ behind the breastbone that works as…
March 1 kicks off NMOSD Awareness Month, which aims every year to shed light on the experiences of people living with neuromyelitis optica spectrum disorder (NMOSD). The Sumaira Foundation (TSF) has led the month-long advocacy initiative in the U.S. since 2016, promoting efforts to spread knowledge about the…
People with neuromyelitis optica spectrum disorder (NMOSD) are at an increased risk of being diagnosed with another autoimmune disease — specifically lupus or Sjögren’s syndrome — according to a large-scale analysis of inpatient hospitalization data in the U.S. In fact, NMOSD patients had a 12 times higher…
Recent Posts
- The pain of NMOSD nerve sensitivity means more than just a cold shoulder
- Most adults with NMOSD use biologic therapies: Registry study
- Every time I turn to Dr. Google, I get an immune system mystery
- Conventional NMOSD treatment effective in double-negative cases
- Grieving how NMOSD has left me uncomfortable in my own skin
- Enspryng outperforms standard immunosuppressants in NMOSD study
- Slow and steady: I’m ditching big resolutions and easing into a new year
- Late-onset NMOSD responds better to newer, highly effective therapies
- New biomarker may help gauge disease severity in NMOSD
- The longest night of the year offers hope of brighter days with NMOSD